An observational study in Influenza, Community-acquired Pneumonia and Cardiovascular Events, sponsored by Kaiser Permanente. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Kaiser Permanente · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.
Among the 966 studies in Influenza, Human with a site in United States, this one is the 3rd largest by planned enrollment of the 122 observational ones that give a count, is one of 42 that started in 2023, is one of 122 observational ones, reaches primary completion later than 34 of the 83 other live ones, and was the 862nd registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
David Moss · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
966 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 244 · Phase 3 127 · Phase 4 147
First in 1997; this study’s year is marked. 42 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500,000 is above the median of 403 across 335 observational studies indexed under Influenza, Human.
Median enrollment 270 across the 843 interventional studies, 261 across the 122 observational. Of the 841 that completed or were terminated, 434 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
435 of 966 have an industry lead sponsor. The 10 most frequent:
Kaiser Permanente is the lead sponsor of 393 studies on the registry; 43 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
Kaiser Permanente has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
41 of the studies in Influenza, Human with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 41 to your calendar (.ics) → With an account.
Among the 966 studies in Influenza, Human with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24, 2024/25, and 2026/27 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.
This study includes KPNC adults ≥65 years who receive Fluad or Fluzone High-Dose influenza vaccine as part of routine clinical care during the 2023/24, 2024/25, and/or 2026/27 influenza seasons.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Kaiser Permanente Northern California members aged ≥65 years who receive Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
Biological: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
Kaiser Permanente Northern California members aged ≥65 years who receive High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.
Also known as: Fluad
Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
Also known as: Fluzone High-Dose
PCR-confirmed influenza
KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for the presence of PCR-confirmed influenza. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons.
Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)
Emergency department visit or hospitalization for PCR-confirmed influenza
KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for an emergency department visit or hospitalization for PCR-confirmed influenza. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons combined.
Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)
Hospitalization for PCR-confirmed influenza
KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for PCR-confirmed influenza. This outcome will be assessed in a pooled analysis across all seasons combined.
Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)
Hospitalization for all-cause community-acquired pneumonia
KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for all-cause community-acquired pneumonia. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons combined.
Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)
Hospitalization for cardiovascular events
KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for cardiovascular events. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons combined.
Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)
PCR-confirmed influenza in subgroups with comorbidities
KPNC members ≥65 years with comorbidities (e.g., cardiovascular and respiratory conditions, diabetes, obesity) who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for PCR-confirmed influenza. This outcome will be assessed in a pooled analysis across all seasons combined.
Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)
Plan to share: No
Started Aug 2023 (actual). Primary completion is estimated for May 2027, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.